Association of Etoricoxib treatment and incident hypoxia in patients with aortic dissection undergoing endovascular aortic repair

• Published in: Biomedicine & pharmacotherapy Vol. 139; p. 111625
• Main Authors: Liao, Huocheng, Ou, Suzhen, Dong, Xiaoyan, Liu, Jianping, Xiao, Chun
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.07.2021; Elsevier
• Subjects: Anti-inflammation; Aortic dissection; Inflammation; CRP; CHF; eGFR; EVAR; AD; OR; LVEF; ALT; Inflammation; IQR; BP; Anti-inflammation; SIRS; NT-proBNP; NSAIDs; Hs-CTnI; Aortic dissection; OSA; CKD; CHD; BMI; COPD; PVD
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2021.111625

The current study was to evaluate the association of Etoricoxib treatment and incident hypoxia among type-B aortic dissection (AD) patients undergoing endovascular aortic repair (EVAR). Patients undergoing EVAR were retrospectively recruited. Based on Etoricoxib use, patients were divided into the non-treated and Etoricoxib-treated groups. Baseline characteristics including demographics, laboratory parameters, characteristics of aortic computer tomography and echocardiography, medications used, and procedural characteristics were collected from the electronic health record. Compared to non-treated group (n = 36), prevalence of obesity and fever at baseline was higher in Etoricoxib-treated group (n = 24; P < 0.05). Mean number of neutrophils, and mean serum CRP and D-dimer levels were higher in Etoricoxib-treated group (P < 0.05). The overall incidence of hypoxia was lower in Etoricoxib-treated group (44.4% vs 33.4%, P < 0.05). Increase in neutrophils count, serum CRP and D-dimer levels was associated with incident hypoxia, with an odds ratio (OR) of 1.36 (95% confidence interval [CI] 1.07–1.65), 1.44 (95% CI 1.12–1.78) and 1.25 (95% CI 1.01–1.47) respectively. In unadjusted model, Etoricoxib use was associated with a 44% lower odds of incident hypoxia. After adjustment for inflammatory markers, the association between Etoricoxib and incident hypoxia was non-significant, with OR of 0.95% and 95% CI of 0.78–1.06. Compared to patients who did not receive Etoricoxib during hospitalization, those treated with Etoricoxib had lower incidence of hypoxia, which might be attributed to its anti-inflammatory effects. Summary of the main findings. AD, aortic dissection; EVAR, endovascular aortic repair. [Display omitted] •Patients with aortic dissection who were treated with Etoricoxib had a lower incidence of hypoxia.•The benefits of Etoricoxib treatment might be attributed to its anti-inflammatory effects.•Etoricoxib treatment was safe and did not increase the risk of cardiovascular and other side effects.